<DOC>
	<DOCNO>NCT01780454</DOCNO>
	<brief_summary>This study examine safety effectiveness combination kidney bone marrow transplant haplo-identical relate donor . An investigational medication treatment give prior transplant help protect transplant kidney attack body 's immune system</brief_summary>
	<brief_title>Renal Allograft Tolerance Through Mixed Chimerism</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Key Male female 1860 year age Candidate livingdonor renal allograft one haplotype identical donor identify . First second transplant either live donor cadaveric transplant first transplant . Positive serologic test EBV indicate past exposure . Key ABO blood groupincompatible renal allograft . Evidence antiHLA antibody within 60 day prior transplant assessed routine methodology ( AHG and/or ELISA ) Positive testing : HIV , hepatitis B core antigen , hepatitis C virus positivity hepatitis B surface antigen . Cardiac ejection fraction &lt; 40 % clinical evidence insufficiency . History cancer basal cell carcinoma skin carcinoma situ cervix . Underlying renal disease etiology high risk disease recurrence transplant kidney ( focal segmental glomerulosclerosis , type I II nonproliferative glomerulonephritis ) . Prior doselimiting radiation therapy . Abnormal ( &gt; 2 time lab normal ) value ( ) liver function chemistry ( ALT , AST , AP ) , ( b ) bilirubin , ( c ) coagulation study ( PT , PTT ) . The presence medical condition investigator deem incompatible participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Chimerism</keyword>
	<keyword>ESRD</keyword>
</DOC>